- Active not recruitingPHASE3
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
This study is looking at different ways of giving a medicine called donanemab for early Alzheimer's disease. Researchers want to see how different doses affect side effects and which patients might be more likely to experience them. It's for adults aged 60-85.
For: Alzheimer's Disease · Dementia · Brain DiseasesUnited States · United Kingdom - Active not recruitingPHASE3
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
This study is testing a new medication called donanemab for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe and helps improve or slow memory and thinking problems. It's a key step in understanding potential new treatments for this condition.
For: Alzheimer Disease · Dementia · Brain DiseasesArgentina · Australia · China - Active not recruitingPHASE3
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)
This study is looking at a new medicine called donanemab for people in the early stages of Alzheimer's disease. Researchers want to find out if it's safe and effective at treating the condition. Some people will get the medicine, and others a dummy treatment.
For: Alzheimer DiseaseUnited States · Australia · Canada